Market closed·Syncing…
Market closed · Close · 19 Nov

Vivimed Labs Limited VIVIMEDLABshare price and chart

Vivimed Labs closed at ₹5.11 on 19 November 2026, down 1.16% on the day. The 52-week range is ₹4.75 to ₹29.40.

₹5.11The price one share last traded at, in rupees.▼ 1.16% · ₹0.06
52-wk low ₹51% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹29

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on VIVIMEDLAB

Real prices, every charge counted. Pick one or write your own.
What Vivimed Labs Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Vivimed Labs began in 1989 as a contract manufacturer of pharmaceutical formulations, started making APIs such as ibuprofen at Bidar, Karnataka in 1991, and moved into specialty chemicals, including the antibacterial Viv-20 supplied to Unilever.

1
1Sector

Pharmaceuticals & Biotechnology

2
2What it sells

APIs, formulations, specialty chemicals

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 19 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
29.2Oversold
0 oversold3070overbought 100
vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.▼ 12.7%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.▼ 18.5%1 monthHow much the share price has changed over the period.▼ 19.3%3 monthsHow much the share price has changed over the period.▼ 9.9%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.30.1%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 31 Mar 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹42 Cr19 NovReturn on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.142.8%full year FY26Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.-34.3%full year FY26Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.00%last 12 monthsFCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.11.0%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Pharmaceuticals · 141 peers · medians
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.-53.15%vs 21.23% median
Lowest: NECLIFE -99.78%Highest: SHUKRAPHAR 652.15%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to March 2026 (results filed 17 Jul 2026), sales fell 53.2% from a year earlier to ₹12.0 cr and the loss was ₹146 cr against ₹5.1 cr a year earlier.

Worth watching
  • Sales fell 4 years running (₹237 cr in FY22 to ₹70.0 cr in FY26).
  • Reported a loss in FY24 and FY25 and FY26.
  • Operating margin fell from -100.1% in FY23 to -216.1% in FY26.
  • Profit before interest covered interest -40.7 times in FY26 (₹4 cr of interest).
  • Promoters had pledged 15.2% of their shares at the end of March 2026, 1.15% of all shares.
  • Promoter holding fell 13.4 points over 8 quarters (20.94% to 7.57%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 10 results, the share rose on 1 and fell on 9, and moved by 3% or more on 6.

+10%
-10%
Q1 FY22Q4 FY22Q3 FY23Q4 FY26

Q4 FY26: results filed 17 Jul 2026. The share went from its close on 16 Jul 2026 to its close on 20 Jul 2026 +3.54%.

Dividend historyCash the company has paid per share, year by year.

₹7,828 in 2018
Paid 2 of 2 yrs
what 2018's payouts come to on ₹1 lakh at today's price · nothing declared in the last twelve months
What each year paid, on ₹1 lakh
7,828
7,828
17
18

2018 paid ₹0.40 per share, about ₹7,828 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
-24.8%a year, over 10 years
1 yr
+3.2%
3 yr
+1.1%
5 yr
-22.4%
10 yr
-24.8%

Held for 10 years this compounded at -24.8% a year. The last twelve months were up +3.2%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
7.57%promoter holding, as of 2026-03-31-21.0 pts since 2021
Promoter share since listing
2021-067.57% now, drawn to its own range2026-03
Who owns it todayas of Mar 26
90.8%
Promoter7.6%Foreign (FII)1.6%Public & others90.8%
Who is buying, who is leavingJun 25 to Mar 26
Promoter7.6%-0.2 pts
Foreign (FII)1.6%steady
Domestic (DII)0.0%steady

Each line is that holder's share of all shares over the last 4 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Promoter pledgeThe share of promoters' holdings given to lenders as security for a loan.15.18%of promoter shares, as at 2026-03-31

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Clarification - Financial Results22-Oct-2026

The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Impact of Audit Qualifications in case of modified opinion(s) The response of the Company is awaited.

Outcome of Board Meeting15-Oct-2026

Vivimed Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Updates28-Sep-2026

Vivimed Labs Limited has informed the Exchange regarding 'COC meeting'.

General Updates26-Sep-2026

Vivimed Labs Limited has informed the Exchange about General Updates

Trading Window23-Sep-2026

Vivimed Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Corporate Insolvency Resolution Process08-Sep-2026

Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process

Corporate Insolvency Resolution Process17-Aug-2026

Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process

Clarification - Financial Results31-Jul-2026

The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.

Updates22-Jul-2026

Vivimed Labs Limited has informed the Exchange regarding 're lodgment'.

General Updates22-Jul-2026

Vivimed Labs Limited has informed the Exchange about General Updates

Certificate under SEBI (Depositories and Participants) Regulations, 201810-Jul-2026

Vivimed Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Trading Window30-Jun-2026

Vivimed Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Reply to Clarification- Financial results25-Jun-2026

The Exchange had sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.

Disclosure under SEBI Takeover Regulations17-Jun-2026

Vivimed Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Corporate Insolvency Resolution Process17-Jun-2026

Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process

Backtest idea · VIVIMEDLABMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on VIVIMEDLAB
Backtest idea · VIVIMEDLABLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on VIVIMEDLAB
Backtest idea · VIVIMEDLABSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on VIVIMEDLAB
Your own ideaWrite a rule for VIVIMEDLAB in plain English“Buy VIVIMEDLAB when …”
Start writing
Buy the dip on VIVIMEDLABBuy when RSI(14) drops below 30
52-week high breakout on VIVIMEDLABBuy when closes at a 52-week high
Golden cross on VIVIMEDLABBuy when 50-day EMA crosses above 200-day
Stochastic oversold on VIVIMEDLABBuy when stochastic %K drops below 20
Pullback in an uptrend on VIVIMEDLABBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹42 cr
Larger than 4% of 141 peers
sector middle ₹2,738 cr
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
142.8%
Highest of 109 peers
sector middle 12.3%
FY25 120.3%FY26 142.8%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
-34.3%
Lowest of 124 peers
sector middle 15.0%
FY23 -70.5%FY26 -34.3%
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.0%
Lower than 56% of 141 peers
sector middle 0.1%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
-53.1%
Lower than 98% of 130 peers
sector middle +21.2%
FY23 -21.2%FY26 -39.8%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY22FY23FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.-216.1%FY26SalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹70 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹-175 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹0.0 as profit. Other income added ₹9.0.

Where it wentPer ₹100 of sales
Running costs₹316.1Depreciation₹37.3Interest₹6.0Tax₹0.3
Profit per ₹100, year by year
FY22FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales▼ 27.9%-▼ 53.1%
Profit---
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash rose by ₹1 Cr, after ₹0 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹8 Cr
Investing-₹1 Cr
Lenders and shareholders-₹6 Cr
Net change in cash+₹1 Cr

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY23FY24FY25FY26
Sales growthSales in this financial year against the previous one.-21.2%-20.3%-22.0%-39.8%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.-100%-22.5%-4.8%-216%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.-176%-31.3%-21.0%-251%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.··120%143%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.-70.5%-11.0%-4.8%-34.3%
Interest coverHow many times the company's profit before interest could pay its interest bill.-8.2x-18.1x-7.4x-40.7x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · VIVIMEDLABStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on VIVIMEDLAB
Backtest idea · VIVIMEDLABPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on VIVIMEDLAB
Backtest idea · VIVIMEDLABBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on VIVIMEDLAB
Backtest idea · VIVIMEDLAB52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on VIVIMEDLAB
Backtest idea · VIVIMEDLABGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on VIVIMEDLAB
MACD momentum on VIVIMEDLABBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on VIVIMEDLABBuy when closes below the lower Bollinger band
Supertrend rider on VIVIMEDLABBuy when supertrend turns up
Buy the dip on VIVIMEDLABBuy when RSI(14) drops below 30
52-week high breakout on VIVIMEDLABBuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Pharmaceuticals
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
SUNPHARMA
Sun Pharmaceutical Industries Limited
4.56 L cr41.6x5.1x14.7%19.1%0.0317.8%+11.9%0.84%
DIVISLAB
Divi's Laboratories Limited
2.97 L cr88.2x16.5x16.2%21.5%0.0027.6%+35.4%0.27%
TORNTPHARM
Torrent Pharmaceuticals Limited
1.75 L cr77.9x9.6x17.0%15.2%0.7612.1%+50.8%0.82%
LAURUSLABS
Laurus Labs Limited
1.25 L cr92.9x20.6x17.7%17.9%0.4017.0%+33.4%0.10%
ZYDUSLIFE
Zydus Lifesciences Limited
1.20 L cr28.9x4.3x18.3%19.9%0.4414.1%+29.2%0.08%
DRREDDY
Dr. Reddy's Laboratories Limited
1.17 L cr41.7x3.0x11.5%13.9%0.158.3%-1.5%0.57%
CIPLA
Cipla Limited
1.15 L cr39.5x3.2x11.7%16.0%0.0110.1%-2.4%0.92%
MANKIND
Mankind Pharma Limited
1.09 L cr48.4x6.2x12.4%12.9%0.3014.7%+17.3%0.00%
AUROPHARMA
Aurobindo Pharma Limited
1.04 L cr26.2x2.6x9.9%12.8%0.2110.8%+23.9%0.39%
LUPIN
Lupin Limited
91,403 cr17.6x3.8x26.9%28.8%0.2317.0%+11.1%0.90%
GLENMARK
Glenmark Pharmaceuticals Limited
73,618 cr50.7x6.6x14.1%20.4%0.089.2%-31.3%0.10%
ALKEM
Alkem Laboratories Limited
61,516 cr29.8x4.1x17.6%20.6%0.1213.4%+13.8%1.03%
BIOCON
Biocon Limited
59,264 cr216.5x1.7x1.1%3.0%0.411.9%+2.2%0.14%
ABBOTINDIA
Abbott India Limited
54,600 cr33.0x----23.0%+11.0%2.55%
GLAND
Gland Pharma Limited
54,336 cr43.9x5.1x10.5%15.0%0.0217.5%+23.3%0.61%
IPCALAB
IPCA Laboratories Limited
47,189 cr33.6x5.4x13.2%16.6%0.0614.2%+13.8%0.32%
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
45,967 cr40.6x24.4x48.9%66.5%0.0027.6%+20.8%2.10%
EMCURE
Emcure Pharmaceuticals Limited
44,481 cr40.7x8.3x19.6%24.8%0.2710.7%+24.3%0.15%
AJANTPHARM
Ajanta Pharma Limited
40,865 cr32.4x8.4x25.4%32.7%0.0220.3%+32.5%0.98%
SAILIFE
Sai Life Sciences Limited
37,985 cr100.5x14.1x15.1%20.9%0.1715.9%+22.5%0.00%
WOCKPHARMA
Wockhardt Limited
35,537 cr86.7x6.9x4.0%6.5%0.3910.8%+23.9%0.00%
ACUTAAS
Acutaas Chemicals Limited
32,561 cr74.1x17.5x23.5%31.7%0.0027.5%+42.7%0.06%
PPLPHARMA
Piramal Pharma Limited
31,906 cr-3.9x-4.0%0.8%0.69-2.1%+28.1%0.00%
RUBICON
Rubicon Research Limited
28,510 cr87.3x20.1x19.1%23.4%0.2815.5%+39.9%0.09%
NEULANDLAB
Neuland Laboratories Limited
27,074 cr59.8x13.3x21.4%27.5%0.1719.6%-12.6%0.16%
APLLTD
Alembic Pharmaceuticals Limited
20,631 cr24.4x3.5x12.4%11.7%0.259.9%+36.3%1.14%
GRANULES
Granules India Limited
19,853 cr27.7x3.0x13.5%15.7%0.0912.1%+20.3%0.22%
ERIS
Eris Lifesciences Limited
18,418 cr25.8x4.4x18.1%13.9%0.5821.6%+12.6%0.54%
ONESOURCE
Onesource Specialty Pharma Limited
18,381 cr-3.1x-1.3%0.4%0.25-0.1%+37.4%0.00%
ALIVUS
Alivus Life Sciences Limited
17,801 cr26.6x4.9x18.4%24.6%0.0024.9%+16.0%0.34%
SHILPAMED
Shilpa Medicare Limited
17,616 cr52.7x6.4x9.8%11.4%0.2418.1%+43.0%0.07%
PFIZER
Pfizer Limited
17,614 cr20.5x4.0x17.2%23.4%0.0032.4%+13.2%1.95%
COHANCE
Cohance Lifesciences Limited
17,578 cr510.5x4.5x5.1%8.0%0.06-0.3%-14.2%0.00%
NATCOPHARM
Natco Pharma Limited
16,124 cr17.8x1.6x16.9%17.1%0.1126.9%-29.0%0.70%
CAPLIPOINT
Caplin Point Laboratories Limited
15,845 cr23.0x4.1x19.9%24.7%0.0029.4%+17.9%0.38%
ASTRAZEN
AstraZeneca Pharma India Limited
15,283 cr86.0x17.4x22.8%31.2%0.006.8%+30.4%0.59%
JUBLPHARMA
Jubilant Pharmova Limited
14,865 cr56.2x2.1x6.0%8.7%0.542.9%+20.5%0.54%
CORONA
CORONA Remedies Limited
13,680 cr66.1x17.0x24.8%27.8%0.1213.3%+22.2%0.45%
MARKSANS
Marksans Pharma Limited
13,556 cr24.2x4.1x25.4%35.1%0.0116.7%+30.5%0.30%
VIVIMEDLAB
Vivimed Labs Limited
42 cr--142.8%-34.3%---53.1%0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-50.0
-14.4
-30.3
+28.4
-0.9
-13.7
-12.4
+36.4
-21.5
+1.6
-7.6
·
-71.1%
11m
2023
-10.1
-18.3
-18.0
-1.5
-11.5
-0.9
-13.2
·
·
·
·
·
-54.8%
7m
2022
-6.9
-13.4
-17.1
+4.8
-12.8
-25.7
+5.1
-5.3
+2.5
-9.9
+3.3
+17.1
-49.5%
2021
-10.3
-4.0
+3.5
+111.2
-12.3
-15.9
-7.2
-12.0
-0.5
-6.4
-2.4
+16.7
+20.2%
2020
+0.8
-13.6
-33.2
+69.7
-15.8
+24.6
-17.1
+96.7
-7.6
-10.0
-2.9
+6.2
+45.0%
2019
-32.0
-12.4
+6.2
+2.6
-12.8
-22.6
-7.5
+2.4
+0.3
-2.9
-14.5
-2.0
-66.1%
2018
-17.4
-9.9
-8.1
+4.6
-16.1
-5.4
-4.2
+15.7
-26.5
-19.0
-1.9
-3.9
-64.7%
2017
+3.2
+16.6
-0.3
+10.3
-5.4
+3.9
+7.0
-19.8
+30.6
-4.4
-7.1
-10.3
+16.1%
2016
·
-5.6
+3.5
+0.9
-7.0
+1.1
-4.0
-3.2
+51.1
-2.0
-8.1
-10.3
+5.1%
11m
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2026-02-10KRONE FINSTOCK PRIVATE LIMITED · bulkSELL5,81,010₹7.41₹0.43 Cr
2026-02-10KRONE FINSTOCK PRIVATE LIMITED · bulkBUY6,010₹7.68₹0.00 Cr
2026-01-20KAMAL JEET GUPTA · bulkBUY4,30,000₹8.17₹0.35 Cr
2026-01-20KAMAL JEET GUPTA · bulkSELL1,30,000₹7.82₹0.10 Cr
2026-01-06NEO APEX VENTURE LLP · bulkBUY10,48,963₹12.25₹1.28 Cr
2026-01-06MERU INVESTMENTS · bulkBUY4,50,000₹12.25₹0.55 Cr
2026-01-06NEO APEX VENTURE LLP · bulkSELL2,98,970₹12.25₹0.37 Cr
2023-04-03A AND S TRADELINK · bulkBUY7,12,573₹6.42₹0.46 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test VIVIMEDLAB. “Buy VIVIMEDLAB when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free